Cargando…

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide

Introduction: This randomized Phase 3 trial evaluated the effect of setmelanotide, a melanocortin 4 receptor agonist, on weight loss, hunger reduction, and safety outcomes in individuals (aged ≥6 years) with obesity and a genetically confirmed diagnosis of Bardet-Biedl syndrome (BBS) or Alström synd...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haws, Robert, Clément, Karine, Dollfus, Hélène, Han, Joan C, Haqq, Andrea Maria, Martos-Moreno, Gabriel Angel, Mittleman, Robert, Stewart, Murray, Webster, Matt, Yanovski, Jack, Yuan, Guojun, Argente, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089587/ http://dx.doi.org/10.1210/jendso/bvab048.002

Ejemplares similares

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
por: Haws, Robert M., et al.
Publicado: (2021)

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020)

MON-LB019 Setmelanotide (RM-493) Reduces Food Intake and Rapidly Induces Weight Loss in a Mouse Model of Alström Syndrome
por: Stephenson, Erin, et al.
Publicado: (2019)

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet–Biedl syndrome: phase 3 trial results
por: Forsythe, Elizabeth, et al.
Publicado: (2023)

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
por: Ervin, Claire, et al.
Publicado: (2023)

PSUN97 Regulation of melanocortin-3 and -4 receptors by isoforms of melanocortin-2 receptor accessory protein 1 and 2
por: Ji, Ren-Lei, et al.
Publicado: (2022)

Bardet-Biedl and Alström syndromes in Spain
por: Valverde, D, et al.
Publicado: (2012)

SAT654 Regulation Of The Melanocortin-4 Receptor (mc4r) By Attractin Like Protein 1 (alp1)
por: Buscaglia, Paul, et al.
Publicado: (2023)

SAT-LB104 Maternal Non-Nutritive Sweeteners Consumption Perturbs Development of Melanocortin Circuits Causing Long-Term Metabolic Alterations in the Offspring
por: Park, Soyoung, et al.
Publicado: (2020)

FRI076 Colchicine Treatment Effects On The Gut Microbiome In Adults With Metabolic Syndrome, Insulin Resistance, And High C-reactive Protein (CRP): A Secondary Analysis Of A Randomized, Placebo-controlled Clinical Trial
por: Kisimba, Celine M, et al.
Publicado: (2023)

SUN-LB016 The Long Term Effects of Resveratrol Supplementation during Pregnancy and Lactation on Adipose Tissue Morphology in the Adult Offspring
por: Ros-Pérez, Purificación, et al.
Publicado: (2019)

OR10-2 Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Abuzzahab, Jennifer, et al.
Publicado: (2022)

RF24 | PSUN94 Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Woloschak, Michael, et al.
Publicado: (2022)

Proteomic and Transcriptomic Landscapes of Alström and Bardet–Biedl Syndromes
por: Smyczynska, Urszula, et al.
Publicado: (2022)

SAT-593 Sex-Specific Modifications in MicroRNAs Contained in Exosomes of Astrocytes in Response to Palmitic Acid
por: Chowen, Julie Ann, et al.
Publicado: (2020)

LBODP003 Effects Of 4-weeks’ Treatment With Intraperitoneal Colchicine On Metabolic And Inflammatory Outcomes In Mice Fed A High-fat Diet
por: Arner, Brooke E, et al.
Publicado: (2022)

Fatty Acids Modify the MicroRNA Content of Exosomes Released by Hypothalamic Astrocytes and the Response of POMC Neurons to These Exosomes
por: Collado-Pérez, Roberto, et al.
Publicado: (2021)

MON-095 Phentermine Induces Weight Loss in Prader-Willi Syndrome
por: Mottalib, Adham, et al.
Publicado: (2019)

MON-587 A Case of Pseudoglucagonoma Syndrome Post Bariatric Surgery
por: Raghunathan, Sapna, et al.
Publicado: (2020)

SAT-LB021 A Comparison of Criteria for Metabolic Syndrome in Nicaraguan Children
por: narvaez, federico
Publicado: (2019)

Longitudinal Weight Gain and Lifestyle Factors in Women With and Without Polycystic Ovary Syndrome
por: Awoke, Mamaru Ayenew, et al.
Publicado: (2021)

FRI054 Partial Lipodystrophy As A Manifestation Of Autoimmune Polyglandular Syndrome 1
por: Agarwal, Shubham, et al.
Publicado: (2023)

SAT672 Dulaglutide Might Reduce Visceral Fat In Patients With Metabolic Syndrome
por: Kim, Yu Na
Publicado: (2023)

SAT663 Determination Of Mitochondrial DNA Mass In Women With Polycystic Ovary Syndrome
por: Rojo, Mailén, et al.
Publicado: (2023)

LBODP109 Astrocytes Affect The Metabolism Of Proopiomelanocortin (pomc) Neurons Through The Release Of Exosomes That Are Modified In A Fatty Acid Specific Manner
por: Collado-Pérez, Roberto, et al.
Publicado: (2022)

MON-LB018 Depot-Specific Differences in Adipose Tissue Morphology with Laron Syndrome
por: Geitgey, Delaney, et al.
Publicado: (2019)

FRI105 Getting Fam-iliar With Familial Chylomicronemia Syndrome: A Case Report
por: Jimenez, Aaron-Ross, et al.
Publicado: (2023)

LBODP002 Phase II Open-label Pilot Trial Of Liraglutide In Adolescents With Obesity After Vertical Sleeve Gastrectomy: Interim Results From 8-weeks Of Treatment
por: Fatima, Syeda Z, et al.
Publicado: (2022)

MON-096 Body Composition in Patients with Craniopharyngioma: Is DXA-Scanning Necessary for Evaluating the Metabolic Syndrome?
por: van Santen, Selveta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3enoauhunuv8m0h43s49bu0v0j